NextCure announced that the FDA has granted Fast Track designation to its investigational drug SIM0505 for treating platinum-resistant ovarian cancer. SIM0505 is an antibody drug conjugate targeting Cadherin-6 with a topoisomerase 1 inhibitor payload, designed to improve treatment outcomes. The Fast Track status will facilitate faster development and regulatory review, with dose optimization in ovarian cancer patients expected to begin in Q2 2026. NextCure also plans to present Phase 1 data at the ASCO 2026 conference, highlighting progress in addressing this urgent unmet medical need.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Latham Group is rated a Buy as it implements a new CEO-led strategy focusing on expanding its core market, increasing presence in the southern U.S., adopting automatic pool covers, and pursuing mergers and acquisitions. Despite challenges in the depr...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
